Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/21/2003US6635253 Composition for enhancing immunological effects
10/21/2003US6635251 Eotaxin-specific antibodies
10/21/2003US6635250 Use of certain metalloproteinase inhibitors for treating nerve disorders mediated by nucleus pulpsus
10/21/2003US6635248 Isolated polypeptide consisting of single chain of amino acids comprising one or more penetrating fragments from one or more penetrating antibodies, which penetrates into cell
10/21/2003CA2257898C Use of aminothiolester derivatives in pharmaceutics
10/21/2003CA2081344C Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
10/16/2003WO2003085377A2 Novel pancortin-pablo protein interactions and methods of use thereof
10/16/2003WO2003085137A1 Antisense modulation of liver glycogen phosphorylase expression
10/16/2003WO2003085125A1 Use of biomolecular targets in the treatment and visualization of brain tumors
10/16/2003WO2003085110A2 Oligomeric compounds for the modulation hif-1alpha expression
10/16/2003WO2003085106A1 Preventives and/or remedies for cancer
10/16/2003WO2003085090A2 A human ribonucleotide reductase m2 subunit
10/16/2003WO2003084610A1 Therapy for psychoses combining an atypical antipsychotic and an mglu2/3 receptor agonist
10/16/2003WO2003084572A1 Medicinal composition comprising acat inhibitor and insuline resistance improving agent
10/16/2003WO2003084567A1 Use of botulinum toxin for treating cardiovasular diseases
10/16/2003WO2003084563A1 Glp-1 agonist and cardiovascular complications
10/16/2003WO2003084560A2 Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
10/16/2003WO2003084558A1 Improved kavalactone profile
10/16/2003WO2003084552A1 Composition for the topical treatment of vulvovaginitis and mycoses
10/16/2003WO2003084545A1 Drug containing riboflavin compound
10/16/2003WO2003084543A1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
10/16/2003WO2003084540A2 Compositions comprising mmp7 modulators for the treatment of chronic pain
10/16/2003WO2003084539A2 New pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
10/16/2003WO2003084538A1 Methods for treating rosacea with pyridones
10/16/2003WO2003084524A1 Combination therapy for the treatment of conditions with pathogenic inflammatory components
10/16/2003WO2003084512A1 Oral delivery of a botanical
10/16/2003WO2003084510A1 Novel pharmaceutical compositions for antihistaminic-decongestant combination and method of making such compositions
10/16/2003WO2003084503A2 P38 kinase inhibitors for treating mucus hypersecretion_
10/16/2003WO2003084485A1 Composition for cell proliferation
10/16/2003WO2003084473A2 Method of treating cancer
10/16/2003WO2003084385A2 Redifferentiated cells for repairing cartilage defects
10/16/2003WO2003084344A2 Method of improving absorption of vitamin e by a pet animal
10/16/2003WO2003084343A2 Method and dietary composition for improving fat digestibility
10/16/2003WO2003084342A2 Method and dietary composition for improving lipid digestibility
10/16/2003WO2003070976A3 Methods for determining the influence of protein binding on antiretroviral activity
10/16/2003WO2003066030A3 Pharmaceutical tablet
10/16/2003WO2003063792A8 Compositions and methods related to tim-3, a th1-specific cell surface molecule
10/16/2003WO2003062443A3 Novel substituted alkane compounds and uses thereof
10/16/2003WO2003061620A3 Peptide-carrying bodies for immune response
10/16/2003WO2003057650A3 Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate
10/16/2003WO2003055410A3 Composition and method for treatment of otitis externa
10/16/2003WO2003054216A3 Antibodies that immunospecifically bind to trail receptors
10/16/2003WO2003053922A3 Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5
10/16/2003WO2003051905A3 Taojiks as modifiers of the beta-catenin pathway and methods of use
10/16/2003WO2003051313A3 Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
10/16/2003WO2003050064A3 Mitotic kinesin inhibitors
10/16/2003WO2003049696A3 Glucosamine organic acid adducts
10/16/2003WO2003048772A3 Detection d'autoanticorps reactifs aux molecules antigenes d'ilots pancreatiques et/ou a l'insuline Detection of autoantibodies reactive molecules to antigens of pancreatic islets and / or insulin
10/16/2003WO2003048164A3 Adenosine a2a receptor antagonists
10/16/2003WO2003047512A3 Compounds derived from an amine nucleus and pharmaceutical compositions comprising same
10/16/2003WO2003047504A3 Prevention and treatment of androgen-deprivation induced osteoporosis
10/16/2003WO2003043668A3 Conditioning solution for contact lenses
10/16/2003WO2003043445A3 Processed baby food with unsaturated fatty acids and/or nucleotides
10/16/2003WO2003041643A3 Hsp90-inhibiting zearalanol compounds and methods of producing and using same
10/16/2003WO2003039478A3 Method and apparatus for the stimulation of hair growth
10/16/2003WO2003039469A3 Heteroaryl derivatives as superior ligands for nociceptin receptor orl-1
10/16/2003WO2003039231A3 Compounds and methods for treating transplant rejection
10/16/2003WO2003033660A3 9136, a human aldehyde dehydrogenase family member and uses therefor
10/16/2003WO2003029434A3 Novel molecules of the hkid-1-related protein family and uses thereof
10/16/2003WO2003029413A3 A novel g protein-coupled receptor, gave 10
10/16/2003WO2003028634A3 Method of treatment using ligand-immunogen conjugates
10/16/2003WO2003026743A3 Opioid formulations having reduced potential for abuse
10/16/2003WO2003026492A3 Prevention and treatment of restenosis by local administration of drug
10/16/2003WO2003022218A3 Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
10/16/2003WO2003015707A3 Method for treating lung cancers
10/16/2003WO2003014391A3 Method for the detection of a polymorphism in cpb2
10/16/2003WO2003011907A3 Receptor, the use thereof, and mouse antibodies
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003005968A3 Dual release levodopa ethyl ester and decarboxylase inhibitor with immediate release levodopa
10/16/2003WO2003005036A3 Epf receptor assays, compounds and therapeutic compositions
10/16/2003WO2003004520A3 Mycobacterial antigens expressed during latency
10/16/2003WO2002100347A3 Prodrugs of gaba analogs, compositions and uses thereof
10/16/2003WO2002099043A3 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002097043A3 Wnv core protein/capsid interacting protein and uses of the same
10/16/2003WO2002094745A3 Non-peptidic cyclophilin binding compounds and their use
10/16/2003WO2002093176A3 Methods for identifying compounds for treatment of ibd
10/16/2003WO2002080884A3 Powder inhaler formulations
10/16/2003WO2002068677A8 Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
10/16/2003WO2002064096A9 Methods of using pyrimidine-based antiviral agents
10/16/2003WO2002064065A3 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation
10/16/2003WO2002056804A3 Presbyopia treatment by lens alteration
10/16/2003WO2002055086A3 Hormone replacement therapy method and its administration form
10/16/2003WO2002054064A3 Method for screening for progesterone receptor isoform-specific ligands
10/16/2003WO2002036118A3 Heterocyclic derivatives useful as pharmaceutical agents
10/16/2003WO2002007673A3 Calcilytic compounds
10/16/2003WO2002003978A3 A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
10/16/2003WO2002000166A3 New compounds useful as antibacterial agents
10/16/2003WO2001088148A3 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/16/2003US20030195461 For perioperatively inhibiting tumor cell adhesion and a variety of pain and inflammation at wounds from general surgical procedures including oral/dental procedures
10/16/2003US20030195362 For therapy of retroviral infection and in particular an HIV infection
10/16/2003US20030195361 Bicyclic pyrrolyl amides as glycogen phosphorylase inhibitors
10/16/2003US20030195261 Administering racemic or optically pure sibutramine metabolite, or a pharmaceutically acceptable salt, solvate, or clathrate for prophylaxis or therapy
10/16/2003US20030195260 Administering R(-) desmethylselegiline in a dosage regimen effective to inhibit, in whole or in part, occurrence or progression of the neoplastic disease or condition
10/16/2003US20030195248 Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
10/16/2003US20030195247 Antagonists of protein tryosin phosphatase 1B (PTP-1B) and T-cell protein tyrosine phosphatase (TC-PTP), used as antidiabetic agents and for prophylaxis of insulin resistance
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195237 Gastrin and cholecystokinin receptor lignads (iv)
10/16/2003US20030195236 Heterocyclic imines such as 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine, used for prophylaxis of vitamin B6 deficiency, cardiovascular disorders or melanomas
10/16/2003US20030195235 Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
1 ... 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 ... 1151